Hiv Salivary Gland Disease: a Role for Viral Infection
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Sjogren's Syndrome an Update on Disease Pathogenesis, Clinical
Clinical Immunology 203 (2019) 81–121 Contents lists available at ScienceDirect Clinical Immunology journal homepage: www.elsevier.com/locate/yclim Review Article Sjogren’s syndrome: An update on disease pathogenesis, clinical T manifestations and treatment ⁎ Frederick B. Vivinoa, , Vatinee Y. Bunyab, Giacomina Massaro-Giordanob, Chadwick R. Johra, Stephanie L. Giattinoa, Annemarie Schorpiona, Brian Shaferb, Ammon Peckc, Kathy Sivilsd, ⁎ Astrid Rasmussend, John A. Chiorinie, Jing Hef, Julian L. Ambrus Jrg, a Penn Sjögren's Center, Penn Presbyterian Medical Center, University of Pennsylvania Perelman School of Medicine, 3737 Market Street, Philadelphia, PA 19104, USA b Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, 51 N. 39th Street, Philadelphia, PA 19104, USA c Department of Infectious Diseases and Immunology, University of Florida College of Veterinary Medicine, PO Box 100125, Gainesville, FL 32610, USA d Oklahoma Medical Research Foundation, Arthritis and Clinical Immunology Program, 825 NE 13th Street, OK 73104, USA e NIH, Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research, Building 10, Room 1n113, 10 Center DR Msc 1190, Bethesda, MD 20892-1190, USA f Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China g Division of Allergy, Immunology and Rheumatology, SUNY at Buffalo School of Medicine, 100 High Street, Buffalo, NY 14203, USA 1. Introduction/History and lacrimal glands [4,11]. The syndrome is named, however, after an Ophthalmologist from Jonkoping, Sweden, Dr Henrik Sjogren, who in Sjogren’s syndrome (SS) is one of the most common autoimmune 1930 noted a patient with low secretions from the salivary and lacrimal diseases. It may exist as either a primary syndrome or as a secondary glands. -
Parotid Sialolithiasis and Sialadenitis in a 3-Year-Old Child
Ahmad Tarmizi et al. Egyptian Pediatric Association Gazette (2020) 68:29 Egyptian Pediatric https://doi.org/10.1186/s43054-020-00041-z Association Gazette CASE REPORT Open Access Parotid sialolithiasis and sialadenitis in a 3- year-old child: a case report and review of the literature Nur Eliana Ahmad Tarmizi1, Suhana Abdul Rahim2, Avatar Singh Mohan Singh2, Lina Ling Chooi2, Ong Fei Ming2 and Lum Sai Guan1* Abstract Background: Salivary gland calculi are common in adults but rare in the paediatric population. It accounts for only 3% of all cases of sialolithiasis. Parotid ductal calculus is rare as compared to submandibular ductal calculus. Case presentation: A 3-year-old boy presented with acute painful right parotid swelling with pus discharge from the Stensen duct. Computed tomography revealed calculus obstructing the parotid duct causing proximal ductal dilatation and parotid gland and masseter muscle oedema. The child was treated with conservative measures, and subsequently the swelling and calculus resolved. Conclusions: Small parotid duct calculus in children may be successfully treated with conservative measures which obviate the need for surgery. We discuss the management of parotid sialolithiasis in children and conduct literature search on the similar topic. Keywords: Sialolithiasis, Sialadenitis, Salivary calculi, Parotid gland, Salivary ducts, Paediatrics Background performing computed tomography (CT) of the neck. Sialolithiasis is an obstructive disorder of salivary ductal The unusual presentation, CT findings and its subse- system caused by formation of stones within the salivary quent management were discussed. gland or its excretory duct [1]. The resulting salivary flow obstruction leads to salivary ectasia, gland dilatation Case presentation and ascending infection [2]. -
Orofacial Manifestations of COVID-19: a Brief Review of the Published Literature
CRITICAL REVIEW Oral Pathology Orofacial manifestations of COVID-19: a brief review of the published literature Esam HALBOUB(a) Abstract: Coronavirus disease 2019 (COVID-19) has spread Sadeq Ali AL-MAWERI(b) exponentially across the world. The typical manifestations of Rawan Hejji ALANAZI(c) COVID-19 include fever, dry cough, headache and fatigue. However, Nashwan Mohammed QAID(d) atypical presentations of COVID-19 are being increasingly reported. Saleem ABDULRAB(e) Recently, a number of studies have recognized various mucocutaneous manifestations associated with COVID-19. This study sought to (a) Jazan University, College of Dentistry, summarize the available literature and provide an overview of the Department of Maxillofacial Surgery and potential orofacial manifestations of COVID-19. An online literature Diagnostic Sciences, Jazan, Saudi Arabia. search in the PubMed and Scopus databases was conducted to retrieve (b) AlFarabi College of Dentistry and Nursing, the relevant studies published up to July 2020. Original studies Department of Oral Medicine and published in English that reported orofacial manifestations in patients Diagnostic Sciences, Riyadh, Saudi Arabia. with laboratory-confirmed COVID-19 were included; this yielded 16 (c) AlFarabi College of Dentistry and Nursing, articles involving 25 COVID-19-positive patients. The results showed a Department of Oral Medicine and Diagnostic Sciences, Riyadh, Saudi Arabia. marked heterogeneity in COVID-19-associated orofacial manifestations. The most common orofacial manifestations were ulcerative lesions, (d) AlFarabi College of Dentistry and Nursing, Department of Restorative Dental Sciences, vesiculobullous/macular lesions, and acute sialadentitis of the parotid Riyadh, Saudi Arabia. gland (parotitis). In four cases, oral manifestations were the first signs of (e) Primary Health Care Corporation, Madinat COVID-19. -
Oral Manifestations of Systemic Disease Their Clinical Practice
ARTICLE Oral manifestations of systemic disease ©corbac40/iStock/Getty Plus Images S. R. Porter,1 V. Mercadente2 and S. Fedele3 provide a succinct review of oral mucosal and salivary gland disorders that may arise as a consequence of systemic disease. While the majority of disorders of the mouth are centred upon the focus of therapy; and/or 3) the dominant cause of a lessening of the direct action of plaque, the oral tissues can be subject to change affected person’s quality of life. The oral features that an oral healthcare or damage as a consequence of disease that predominantly affects provider may witness will often be dependent upon the nature of other body systems. Such oral manifestations of systemic disease their clinical practice. For example, specialists of paediatric dentistry can be highly variable in both frequency and presentation. As and orthodontics are likely to encounter the oral features of patients lifespan increases and medical care becomes ever more complex with congenital disease while those specialties allied to disease of and effective it is likely that the numbers of individuals with adulthood may see manifestations of infectious, immunologically- oral manifestations of systemic disease will continue to rise. mediated or malignant disease. The present article aims to provide This article provides a succinct review of oral manifestations a succinct review of the oral manifestations of systemic disease of of systemic disease. It focuses upon oral mucosal and salivary patients likely to attend oral medicine services. The review will focus gland disorders that may arise as a consequence of systemic upon disorders affecting the oral mucosa and salivary glands – as disease. -
For Immediate Release
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and CEO (Code no.: 4568, First Section, Tokyo, Osaka, and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, General Manager, Corporate Communications Department Telephone: +81-3-6225-1126 http://www.daiichisankyo.com/ Daiichi Sankyo Launches new Cravit® Formulations in Japan TOKYO, Japan (July 7, 2009) – Daiichi Sankyo Company, Limited (TSE: 4568), today launched new formulations of Cravit® (generic name: Levofloxacin Hydrate), a broad-spectrum oral anti-bacterial agent. These formulations are 500mg and 250mg tablets, and a 10% fine granular preparation in Japan. The company obtained manufacturing and marketing approval on April 22. The drug price listing was on June 19. Daiichi Sankyo drew on PK-PD theory (see note below) to develop the once-daily dosage for the 500mg Cravit® tablet. This tablet lifts the maximum blood concentration and is significantly more bactericidal than the 100mg formulation, taken three times daily, suppressing the development of drug-resistant bacteria. The once-daily dosage of the Cravit® 500mg tablet is an approved standard in more than 120 countries and territories. Since its introduction in December 1993 in Japan, Cravit® has gained approval for treating 43 indications and 32 bacteria. This agent continues to offer outstanding efficacy, and has won accolades for its safety profile. Daiichi Sankyo is confident that its concept of a once-daily dosage of a 500mg tablet will win broad acceptance for improved efficacy and a better suppression of strong bacteria. The company will cultivate this product as a worthy contributor to long-term treatment. -
Lymphoepithelial Cyst of the Salivary Gland in a Small Ruminant Lentivirus-Positive Goat
animals Case Report Lymphoepithelial Cyst of the Salivary Gland in a Small Ruminant Lentivirus-Positive Goat Izabella Dolka 1,* , Marek Tomaszewski 2, Daria Wola 2, Michał Czopowicz 3 and Jarosław Kaba 3 1 Department of Pathology and Veterinary Diagnostics, Institute of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159c, 02-776 Warsaw, Poland 2 The Scientific Society of Veterinary Medicine Students, Institute of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159, 02-787 Warsaw, Poland; [email protected] (M.T.); [email protected] (D.W.) 3 Division of Veterinary Epidemiology and Economics, Institute of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159c, 02-776 Warsaw, Poland; [email protected] (M.C.); [email protected] (J.K.) * Correspondence: [email protected] Received: 7 August 2020; Accepted: 30 August 2020; Published: 1 September 2020 Simple Summary: This study presents the first case of a lymphoepithelial cyst (LEC) adjacent to the salivary gland in a goat seropositive for the small ruminant lentivirus (SRLV). Immunohistochemistry detected the antigen of caprine arthritis-encephalitis virus (CAEV) in the LEC, salivary gland, and lung tissue. In human patients, a LEC of the major salivary gland is an uncommon benign lesion and may be the early clinical manifestation of human immunodeficiency virus (HIV) infection. The present report provides useful information on the comparative aspect of LEC in an animal infected with CAEV, one of the SRLVs usually associated with chronic infection. Although many hypothetic theories were proposed, the etiopathogenesis of LEC is still debated. In this study, we present the histopathological description of LEC, supported by histochemistry and immunohistochemistry. -
Herpes: a Patient's Guide
Herpes: A Patient’s Guide Herpes: A Patient’s Guide Introduction Herpes is a very common infection that is passed through HSV-1 and HSV-2: what’s in a name? ....................................................................3 skin-to-skin contact. Canadian studies have estimated that up to 89% of Canadians have been exposed to herpes simplex Herpes symptoms .........................................................................................................4 type 1 (HSV-1), which usually shows up as cold sores on the Herpes transmission: how do you get herpes? ................................................6 mouth. In a British Columbia study, about 15% of people tested positive for herpes simplex type 2 (HSV-2), which Herpes testing: when is it useful? ..........................................................................8 is the type of herpes most commonly thought of as genital herpes. Recently, HSV-1 has been showing up more and Herpes treatment: managing your symptoms ...................................................10 more on the genitals. Some people can have both types of What does herpes mean to you: receiving a new diagnosis ......................12 herpes. Most people have such minor symptoms that they don’t even know they have herpes. What does herpes mean to you: accepting your diagnosis ........................14 While herpes is very common, it also carries a lot of stigma. What does herpes mean to you: dating with herpes ....................................16 This stigma can lead to anxiety, fear and misinformation -
Prevalence of Salivary Gland Disease in Patients Visiting a Private Dental
European Journal of Molecular & Clinical Medicine ISSN 2515-8260 Volume 07, Issue 01, 2020 PREVALENCE OF SALIVARY GLAND DISEASE IN PATIENTS VISITING A PRIVATE DENTAL COLLEGE 1Dr.Abarna Jawahar, 2Dr.G.Maragathavalli, 3Dr.Manjari Chaudhary 1Department of Oral Medicine and Radiology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, India 2Professor, Department of Oral Medicine and Radiology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences(SIMATS), Saveetha University, Chennai, India 3Senior Lecturer, Department of Oral Medicine and Radiology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences(SIMATS), Saveetha University, Chennai, India [email protected] [email protected] [email protected] ABSTRACT: The aim of the study was to estimate the prevalence of salivary gland diseases in patients visiting a private dental college. A retrospective analysis was conducted on patients who visited the Department of Oral Medicine from March 2019 to March 2020.Clinically diagnosed cases of salivary gland diseases which included salivary gland neoplasms, xerostomia, necrotizing sialometaplasia, mucocele, ranula, sjogren’s syndrome, sialodochitis, sialadenitis were included in the study.The details of each case were reviewed from an electronic database.From the study we found that 17 patients were diagnosed with salivary gland disease.The most commonly observed salivary gland disease was mucocele of the lip with a frequency of 41.17% in the study population followed by xerostomia (17.65%).Salivary gland disease can occur due to variable causes and might significantly affect the quality of life and daily functioning.Only with a thorough knowledge of the subject it is possible to detect the diseases of the salivary gland in their early stage and manage them more efficiently. -
Salivary Gland Imaging in Sjogren's Syndrome
REVIEW Salivary gland imaging in Sjogren’s syndrome Susan I Lemon, Sjogren’s syndrome (SS) is a systemic connective tissue disease characterized by a Steven G Imbesi & progressive immune-mediated impairment of the exocrine glands. The high prevalence in Alexander R Shikhman† the general population of sicca and other symptoms mimicking SS has increased the need †Author for correspondence for accurate tools in its diagnosis. Imaging may be substantially helpful in this regard, as Scripps Clinic, Member of the well as in the assessment of acute and chronic complications of the disease. A future Division of Rheumatology, MS113, 10666 North Torrey, application of salivary imaging in SS may be guiding therapeutics by enabling Pines Road, La Jolla, radiographic monitoring of treatment responsiveness. This review of salivary gland imaging CA 92037, USA in SS summarizes the types of information yielded by currently available modalities and Tel.: +1 858 554 8562; suggests their proper clinical application. It emphasizes recent advances in noninvasive Fax: +1 858 554 6763; imaging, including magnetic resonance sialography, ultrasonography and nuclear [email protected] medicine techniques. Sjogren’s syndrome (SS) is a systemic connective atrophic and, finally, destroyed [8]. Eventually, the tissue disease characterized by a progressive only remaining ductal epithelium consists of iso- immune-mediated impairment of the exocrine lated cell clusters of epithelial and myoepithelial glands [1,2]. Common clinical manifestations of cells surrounded by a dense lymphocytic infiltra- exocrine involvement in SS include keratocon- tion (a benign lymphoepithelial lesion) [9]. These junctivitis sicca, xerostomia and episodic glandu- pathological changes lead to salivary gland hypo- lar swelling. -
BIMJ April 2013
Original Article Brunei Int Med J. 2013; 9 (5): 290-301 Yellow lesions of the oral cavity: diagnostic appraisal and management strategies Faraz MOHAMMED 1, Arishiya THAPASUM 2, Shamaz MOHAMED 3, Halima SHAMAZ 4, Ramesh KUMARASAN 5 1 Department of Oral & Maxillofacial Pathology, Dr Syamala Reddy Dental College Hospital & Research Centre, Bangalore, India 2 Department of Oral Medicine & Radiology, Dr Syamala Reddy Dental College Hospital & Research Centre, Bangalore, India 3 Department of Community & Public Health Dentistry, Faculty of Dentistry, Amrita University, Cochin, India 4 Amrita center of Nanosciences, Amrita University, Cochin, India 5 Oral and Maxillofacial Surgery, Faculty of Dentistry, AIMST University, Kedah, Malaysia ABSTRACT Yellow lesions of the oral cavity constitute a rather common group of lesions that are encountered during routine clinical dental practice. The process of clinical diagnosis and treatment planning is of great concern to the patient as it determines the nature of future follow up care. There is a strong need for a rational and functional classification which will enable better understanding of the basic disease process, as well as in formulating a differential diagnosis. Clinical diagnostic skills and good judgment forms the key to successful management of yellow lesions of the oral cavity. Keywords: Yellow lesions, oral cavity, diagnosis, management INTRODUCTION INTRODUCTI Changes in colour have been traditionally low lesions have a varied prognostic spec- used to register and classify mucosal and soft trum. The yellowish colouration may be tissue pathology of the oral cavity. Thus, the- caused by lipofuscin (the pigment of fat). It se lesions have been categorised as white, may also be the result of other causes such red, white and red, blue and/or purple, as accumulation of pus, aggregation of lym- brown, grey and/or black and yellow. -
Hairy Leukoplakia James E
Marquette University e-Publications@Marquette School of Dentistry Faculty Research and Dentistry, School of Publications 5-5-2017 Hairy Leukoplakia James E. Cade Meharry Medical College School of Dentistry Richard P. Vinson Paul L Foster School of Medicine Jeff urB gess University of Washington School of Dental Medicine Sanjiv S. Agarwala Temple University Shool of Medicine Denis P. Lynch Marquette University, [email protected] See next page for additional authors Published version. Medscape Drugs & Diseases (May 5, 2017). Publisher link. © 2017 by WebMD LLC. Used with permission. Authors James E. Cade, Richard P. Vinson, Jeff urB gess, Sanjiv S. Agarwala, Denis P. Lynch, and Gary L. Stafford This blog post/website is available at e-Publications@Marquette: https://epublications.marquette.edu/dentistry_fac/252 Overview Background Oral hairy leukoplakia (OHL) is a disease of the mucosa first described in 1984. This pathology is associated with Epstein-Barr virus (EBV) and occurs mostly in people with HIV infection, both immunocompromised and immunocompetent, and can affect patients who are HIV negative.{ref1}{ref2} The first case in an HIV-negative patient was reported in 1999 in a 56-year-old patient with acute lymphocytic leukemia. Later, many cases were reported in heart, kidney, and bone marrow transplant recipients and patients with hematological malignancies.{ref3}{ref4} Pathophysiology The Epstein-Barr virus (EBV), a ubiquitous herpesvirus estimated to infect 90% of the world's population, is linked to a growing number of diseases, especially in immunocompromised hosts. Like all herpesviruses, EBV establishes a life-long, persistent infection of its host. The pathogenesis of hairy leukoplakia is clearly complex, potentially requiring a convergence of factors including EBV co-infection, productive EBV replication, EBV genetic evolution, expression of specific EBV "latent" genes, and immune escape. -
Pathogenic Viruses Commonly Present in the Oral Cavity and Relevant Antiviral Compounds Derived from Natural Products
medicines Review Pathogenic Viruses Commonly Present in the Oral Cavity and Relevant Antiviral Compounds Derived from Natural Products Daisuke Asai and Hideki Nakashima * Department of Microbiology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan * Correspondence: [email protected]; Tel.: +81-44-977-8111 Received: 24 October 2018; Accepted: 7 November 2018; Published: 12 November 2018 Abstract: Many viruses, such as human herpesviruses, may be present in the human oral cavity, but most are usually asymptomatic. However, if individuals become immunocompromised by age, illness, or as a side effect of therapy, these dormant viruses can be activated and produce a variety of pathological changes in the oral mucosa. Unfortunately, available treatments for viral infectious diseases are limited, because (1) there are diseases for which no treatment is available; (2) drug-resistant strains of virus may appear; (3) incomplete eradication of virus may lead to recurrence. Rational design strategies are widely used to optimize the potency and selectivity of drug candidates, but discovery of leads for new antiviral agents, especially leads with novel structures, still relies mostly on large-scale screening programs, and many hits are found among natural products, such as extracts of marine sponges, sea algae, plants, and arthropods. Here, we review representative viruses found in the human oral cavity and their effects, together with relevant antiviral compounds derived from natural products. We also highlight some recent emerging pharmaceutical technologies with potential to deliver antivirals more effectively for disease prevention and therapy. Keywords: anti-human immunodeficiency virus (HIV); antiviral; natural product; human virus 1. Introduction The human oral cavity is home to a rich microbial flora, including bacteria, fungi, and viruses.